These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 9294466)
1. Cost of combined modality interventions for stage III non-small-cell lung cancer. Evans WK; Will BP; Berthelot JM; Earle CC J Clin Oncol; 1997 Sep; 15(9):3038-48. PubMed ID: 9294466 [TBL] [Abstract][Full Text] [Related]
2. Cost-effectivenes of paclitaxel plus cisplatin in advanced non-small-cell lung cancer. Earle CC; Evans WK Br J Cancer; 1999 May; 80(5-6):815-20. PubMed ID: 10360660 [TBL] [Abstract][Full Text] [Related]
3. Diagnostic and therapeutic approaches to lung cancer in Canada and their costs. Evans WK; Will BP; Berthelot JM; Wolfson MC Br J Cancer; 1995 Nov; 72(5):1270-7. PubMed ID: 7577481 [TBL] [Abstract][Full Text] [Related]
4. Estimating the cost of lung cancer diagnosis and treatment in Canada: the POHEM model. Evans WK; Will BP; Berthelot JM; Wolfson MC Can J Oncol; 1995 Dec; 5(4):408-19. PubMed ID: 8770457 [TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of vinorelbine alone or vinorelbine plus cisplatin for stage IV NSCLC. Evans WK Oncology (Williston Park); 1998 Mar; 12(3 Suppl 4):18-25; discussion 25-6. PubMed ID: 9556779 [TBL] [Abstract][Full Text] [Related]
6. Economic analysis of the TAX 317 trial: docetaxel versus best supportive care as second-line therapy of advanced non-small-cell lung cancer. Leighl NB; Shepherd FA; Kwong R; Burkes RL; Feld R; Goodwin PJ J Clin Oncol; 2002 Mar; 20(5):1344-52. PubMed ID: 11870178 [TBL] [Abstract][Full Text] [Related]
7. A Cost-Effectiveness Analysis of Using the JBR.10-Based 15-Gene Expression Signature to Guide Adjuvant Chemotherapy in Early Stage Non-Small-Cell Lung Cancer. Wong KM; Ding K; Li S; Bradbury P; Tsao MS; Der SD; Shepherd FA; Chung C; Ng R; Seymour L; Leighl NB Clin Lung Cancer; 2017 Jan; 18(1):e41-e47. PubMed ID: 27502323 [TBL] [Abstract][Full Text] [Related]
8. Metastatic non-small cell lung cancer: costs associated with disease progression. Fox KM; Brooks JM; Kim J Am J Manag Care; 2008 Sep; 14(9):565-71. PubMed ID: 18778171 [TBL] [Abstract][Full Text] [Related]
9. Influence of conformal radiotherapy technique on survival after chemoradiotherapy for patients with stage III non-small cell lung cancer in the National Cancer Data Base. Sher DJ; Koshy M; Liptay MJ; Fidler MJ Cancer; 2014 Jul; 120(13):2060-8. PubMed ID: 24692108 [TBL] [Abstract][Full Text] [Related]
10. Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer. Choi NC; Carey RW; Daly W; Mathisen D; Wain J; Wright C; Lynch T; Grossbard M; Grillo H J Clin Oncol; 1997 Feb; 15(2):712-22. PubMed ID: 9053497 [TBL] [Abstract][Full Text] [Related]
11. Combined modality therapy of non-small cell lung cancers. Juretic A; Sobat H; Samija M Ann Oncol; 1999; 10 Suppl 6():93-8. PubMed ID: 10676559 [TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of gemcitabine in stage IV non-small cell lung cancer: an estimate using the Population Health Model lung cancer module. Evans WK Semin Oncol; 1997 Apr; 24(2 Suppl 7):S7-56-S7-63. PubMed ID: 9194482 [TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of continuation maintenance pemetrexed after cisplatin and pemetrexed chemotherapy for advanced nonsquamous non-small-cell lung cancer: estimates from the perspective of the Chinese health care system. Zeng X; Peng L; Li J; Chen G; Tan C; Wang S; Wan X; Ouyang L; Zhao Z Clin Ther; 2013 Jan; 35(1):54-65. PubMed ID: 23328269 [TBL] [Abstract][Full Text] [Related]
14. Adjuvant radiotherapy and chemotherapy for stage II or IIIA non-small-cell lung cancer after complete resection. Provincial Lung Cancer Disease Site Group. Logan DM; Lochrin CA; Darling G; Eady A; Newman TE; Evans WK Cancer Prev Control; 1997 Dec; 1(5):366-78. PubMed ID: 9765759 [TBL] [Abstract][Full Text] [Related]
15. Sequential combined modality therapy for stage III non-small cell lung cancer. Vokes EE Hematol Oncol Clin North Am; 1990 Dec; 4(6):1133-42. PubMed ID: 1962780 [TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness of neoadjuvant chemoradiotherapy versus chemotherapy alone followed by surgery for patients with stage IIIA non-small cell lung cancer. Sher DJ; Fidler MJ; Liptay MJ; Koshy M Lung Cancer; 2015 Jun; 88(3):267-74. PubMed ID: 25862147 [TBL] [Abstract][Full Text] [Related]
17. Results of trimodality therapy in patients with stage IIIA (N2-bulky) and stage IIIB non-small-cell lung cancer. Li J; Dai CH; Yu LC; Chen P; Li XQ; Shi SB; Wu JR Clin Lung Cancer; 2009 Sep; 10(5):353-9. PubMed ID: 19808194 [TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China. Wu B; Chen H; Shen J; Ye M Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806 [TBL] [Abstract][Full Text] [Related]
19. 18FDG-PET-CT in the follow-up of non-small cell lung cancer patients after radical radiotherapy with or without chemotherapy: an economic evaluation. van Loon J; Grutters JP; Wanders R; Boersma L; Dingemans AM; Bootsma G; Geraedts W; Pitz C; Simons J; Brans B; Snoep G; Hochstenbag M; Lambin P; De Ruysscher D Eur J Cancer; 2010 Jan; 46(1):110-9. PubMed ID: 19944595 [TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancer. Klein R; Wielage R; Muehlenbein C; Liepa AM; Babineaux S; Lawson A; Schwartzberg L J Thorac Oncol; 2010 Aug; 5(8):1263-72. PubMed ID: 20581708 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]